In its first full year on the U.S. market, bladder cancer treatment Adstiladrin earned about $77 million. Elsewhere, Lilly ...

Shares in many large drugmakers initially fell Wednesday on the president's threat, only to rebound later when he announced a ...

Drug company shares, which had sunk on comments by Trump that pharma duties would be coming soon, rallied along with the ...

There will be a ChatGPT moment for biotechnology,” a bipartisan commission wrote in the new report, which calls for the U.S.

La., had invited Kennedy to testify April 10 on the sweeping layoffs of federal health workers Kennedy ordered last month. A ...

We, like so many others, have been forced to take steps to extend our cash runway,” said Tango’s CEO, citing “extremely ...

The company has decided to switch gears following disappointing data for a monoclonal antibody targeting a rare maternal ...

Study results in a rare form of obesity could help the company expand use of Imcivree, which is approved for two genetically ...

The pharma giant is wagering potentially billions of dollars on technology from ABL Bio that’s designed to get drugs across ...

Cellular Therapies and IDRx, crossed the $1 billion mark, a notable decrease from the six seen during the same period last ...

Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.

The president will impose a baseline 10% tariff on all countries, as well as higher levies on certain nations. Pharmaceutical ...